ProfileGDS5678 / 1455048_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 35% 35% 27% 36% 33% 32% 66% 36% 37% 35% 39% 35% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7348631
GSM967853U87-EV human glioblastoma xenograft - Control 22.7976435
GSM967854U87-EV human glioblastoma xenograft - Control 32.7985135
GSM967855U87-EV human glioblastoma xenograft - Control 42.5636227
GSM967856U87-EV human glioblastoma xenograft - Control 52.7668836
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8320833
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7810532
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9628866
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8021636
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8334137
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7906735
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8612939
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7971935
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7888835